Previous close | 0.3643 |
Open | 0.3600 |
Bid | 0.3501 x 1000 |
Ask | 0.3800 x 1000 |
Day's range | 0.3501 - 0.3698 |
52-week range | 0.3500 - 2.3400 |
Volume | |
Avg. volume | 465,741 |
Market cap | 33.265M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, January 17, 2023--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. ("Veris"), a private digital health company focused on enhanced personalized cancer care, today provided a
NEW YORK, January 11, 2023--Companies will present refinements to their business strategy as each continue to the benefit patients in need and create value for shareholders.
NEW YORK, December 22, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. ("Novosound"), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound’s proprietary flexible thin-film ultrasound technology in me